Navigation Links
Savient Pharmaceuticals Reports Third Quarter 2009 Financial Results
Date:11/4/2009

our proposed secondary source supplier of pegloticase active pharmaceutical ingredient (API). We also incurred $1.0 million in higher expenses resulting from increased outside laboratory testing services supporting our OLE study for KRYSTEXXA.

Selling, general and administrative expenses for the third quarter of 2009 were $8.5 million, compared with $7.6 million for the third quarter of 2008, an increase of $0.9 million, or 13%, primarily due to severance expense related to our plan of termination that reduced our workforce by 25 employees in the third quarter of 2009.

Investment income, net for the third quarter of 2009 was $0.5 million, compared with $0.3 million for the three months ended September 30, 2008, an increase of $0.2 million, or 48%, primarily due to realized gains on the sale of short-term investments.

Other income, net for the third quarter of 2009 was $11.8 million, compared with Other expense, net of $0.1 million for the third quarter of 2008, an increase to income of $11.9 million as a result of the non-cash gain on the mark-to-market valuation adjustment to our warrant liability during the three months ended September 30, 2009.

Financial Results of Operations for the Nine Months Ended September 30, 2009

Total revenues for the first nine months of 2009 were $2.1 million, consistent with the same period of 2008.

Research and development expenses for the first nine months of 2009 were $42.1 million, compared with $37.8 million for the same period of 2008, an increase of $4.3 million, or 11%. The increase was primarily due to higher expenses of $3.5 million associated with the production of pegloticase API commercial batches at BTG, severance expense of $2.5 million recorded during the current year and contingency charges of $4.5 million recorded in the third quarter of 2009 relating to amending the fee schedule and total obligation under a services agreement for the manuf
'/>"/>

SOURCE Savient Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related medicine technology :

1. Savient Announces FDAs Advisory Panel to Review Pegloticase for Treatment-Failure Gout Patients
2. Savient Provides Update on Pegloticase BLA
3. Savient Pharmaceuticals Announces Proposed Public Offering of Common Stock
4. Savient Pharmaceuticals Prices Underwritten Offering of Common Stock
5. Savient Pharmaceuticals Announces Closing of Public Offering and Exercise of Over-Allotment Option
6. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
7. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
8. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
9. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
10. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
11. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/16/2009)... -- Sanofi Pasteur, the vaccines ... that it has entered into an exclusive, ... and commercialize its prophylactic vaccine against ... or MRSA. MRSA are responsible for ... to as multidrug-resistant Staphylococcus aureus ...
(Date:12/16/2009)... BioSpecifics Technologies Corp. (Nasdaq: BSTC ), a ... today announced top-line efficacy and safety results from ... the treatment of Peyronie,s disease. Peyronie,s disease is ... the shaft of the penis, which can distort ... impossible in advanced cases. The Phase 2b study, ...
(Date:12/16/2009)... WOONSOCKET, R.I., Dec. 16 CVS/pharmacy and ... stores are now offering H1N1 vaccine in 20 ... locations priority restrictions for receiving H1N1 vaccines continue, ... to be eligible to receive the shot while ... has been restocked and is available at MinuteClinic ...
Breaking Medicine Technology:Sanofi Pasteur Obtains License from Syntiron to Develop & Commercialize Vaccine to Prevent Staphylococcus Infections 2Sanofi Pasteur Obtains License from Syntiron to Develop & Commercialize Vaccine to Prevent Staphylococcus Infections 3Sanofi Pasteur Obtains License from Syntiron to Develop & Commercialize Vaccine to Prevent Staphylococcus Infections 4BioSpecifics Technologies Corp. Announces Top-Line Phase 2b Results for XIAFLEX(TM) for Treatment of Peyronie's Disease 2BioSpecifics Technologies Corp. Announces Top-Line Phase 2b Results for XIAFLEX(TM) for Treatment of Peyronie's Disease 3BioSpecifics Technologies Corp. Announces Top-Line Phase 2b Results for XIAFLEX(TM) for Treatment of Peyronie's Disease 4CVS/pharmacy and MinuteClinic Providing H1N1 Vaccines in 20 States and Washington, D.C. 2CVS/pharmacy and MinuteClinic Providing H1N1 Vaccines in 20 States and Washington, D.C. 3CVS/pharmacy and MinuteClinic Providing H1N1 Vaccines in 20 States and Washington, D.C. 4Atrial fibrillation in endurance athletes still poses problems for sports cardiologists 49549 1Atrial fibrillation in endurance athletes still poses problems for sports cardiologists 49549 2Atrial fibrillation in endurance athletes still poses problems for sports cardiologists 49549 3METTLER TOLEDO Introduces an Affordable Reaction Block for Solid Phase Peptide Synthesis 28SPPS 29 12714 1METTLER TOLEDO Introduces an Affordable Reaction Block for Solid Phase Peptide Synthesis 28SPPS 29 12714 2Does Location Affect Kids Weight 3F 49542 1Does Location Affect Kids Weight 3F 49542 2
... a study published in The American Journal of ... Clinic psychiatrist Mark Frye, M.D., attempted to identify what ... to experience treatment-emergent mania (TEM).Bipolar disorder, also known as ... mood instability that can be serious and disabling. The ...
... for Type 2 Diabetes-PLYMOUTH MEETING, Pa., Feb. 10 ... promising preliminary Phase 1b clinical data for trodusquemine (MSI-1436), ... lead drug candidate for the treatment of type 2 ... CEO of Genaera, presented data from the first of ...
Other Medicine Technology:Study Suggests New Treatment Approach May be Needed for Management of Depression in Some People With Bipolar Disorder 2Study Suggests New Treatment Approach May be Needed for Management of Depression in Some People With Bipolar Disorder 3Genaera Presents Preliminary Phase 1b Data for Trodusquemine (MSI-1436) 2Genaera Presents Preliminary Phase 1b Data for Trodusquemine (MSI-1436) 3
(Date:12/17/2009)... 17 Researchers from the School of ... in the UK are today,encouraging families worldwide ... Year following concerning research* that shows two-thirds of ... a family (68%), with the,Portuguese being the least ... together. , According to ...
(Date:12/17/2009)... over the past three years and what has driven these changes ... ... Morehead, the human capital research firm, will host a webinar titled ... free hour-long webinar will be broadcast on Wednesday, January 27, 2010 ... Morehead’s SVP, Consulting Services and Trevor Byrd, Ph.D., a Morehead Consultant, ...
(Date:12/17/2009)... Healthcare Cost/Risk Analysis reports, activity measures and outcomes reporting to ... toward reduced claim costs and positive return on investment over ... ... Jacksonville, FL (PRWEB) December 17, 2009 -- ... in clinical/claims based cost risk analysis along with personalized nurse ...
(Date:12/16/2009)... -- If proposed health care legislation is enacted, ... insurance system. Approximately 18.4 million Californians and 161 ... upon employer-based insurance for their health care coverage. ... reform legislation entail specific requirements for employer-based insurance. ... for firms that currently comply with most new ...
(Date:12/16/2009)... Annual Gala Raises Significant Funds to Benefit of Children ... Christine Taylor, Gary Cole and Zachary Levi Join ... ,, LOS ANGELES, Dec. 16 At its ... three remarkable individuals. Hasbro President & CEO ... Award in recognition of his far-reaching philanthropic leadership ...
Breaking Medicine News(10 mins):Health News:The Family Walk - a Dying Tradition Around the World? 2Health News:Morehead Presents Webinar on "The State of Employee Engagement: A Year in Review" 2Health News:Baptist Health System Selects HealthScreen Disease Management for Employee Health Management Services 2Health News:How National Health Reform Proposals Would Affect Employer-Based Plans in California 2Health News:How National Health Reform Proposals Would Affect Employer-Based Plans in California 3Health News:The Help Group Honors Brian Goldner, Mary Urquhart and Max Mayer at its Teddy Bear Ball Featuring Ben Stiller and Celebrity Guests 2Health News:The Help Group Honors Brian Goldner, Mary Urquhart and Max Mayer at its Teddy Bear Ball Featuring Ben Stiller and Celebrity Guests 3Health News:The Help Group Honors Brian Goldner, Mary Urquhart and Max Mayer at its Teddy Bear Ball Featuring Ben Stiller and Celebrity Guests 4Health News:The Help Group Honors Brian Goldner, Mary Urquhart and Max Mayer at its Teddy Bear Ball Featuring Ben Stiller and Celebrity Guests 5
... Light of New Evidence Showing the,Benefits of UV ... Today, the Indoor,Tanning Association (ITA) launched an ... and criticizing,dermatologists and the sunscreen and cosmetics industries ... advertising blitz begins with a full-page print ad ...
... Md. (March 26, 2008) -- The American Physiological Society ... the 2008 Henry Pickering Bowditch Memorial Award for early-career ... 42 years whose accomplishments are both original and outstanding. ... a professor of pharmacology and toxicology, has focused her ...
... Visiprise, Inc., a leader in,manufacturing execution systems (MES) ... named to START-IT magazine,s START-IT 125 list., ... editors and editorial advisors,of START-IT magazine to recognize ... market., Visiprise,s flagship solution, Visiprise Manufacturing, is ...
... Needed, Experts Say, PHILADELPHIA, March 26 ... group of healthcare leaders based at the,University of ... convene a,special conference to address the national shortage ... cannot be maintained, let alone,expanded, unless we educate ...
... 26 WPCS International,Incorporated (Nasdaq: WPCS ... specialty communication systems and wireless infrastructure, has,announced ... awarded approximately,$12 million in new contracts., ... for The University of,Connecticut, The Mashantucket Pequot ...
... ... BIG HORN, Wyo., March 26 Gourmetceuticals, LLC, ... for use in foods and beverages, today announced ... booster, and,PPL-240, an antioxidant, will be presented at ...
Other Medicine News:Health News:Indoor Tanning Association Launches Campaign Attacking Melanoma Hype 2Health News:MSU professor earns Bowditch Award for work on hypertension 2Health News:MSU professor earns Bowditch Award for work on hypertension 3Health News:Visiprise Named One of the Top Manufacturing Technology Providers 2Health News:Council Calls on White House to Convene Conference on Physician and Nurse Supply 2Health News:WPCS Announces $12 Million in New Projects 2Health News:Gourmetceuticals to Present Data from Four Studies at Experimental Biology 2008 2
Allows surgeons to successfully complete coronary artery bypass without cross clamping or side biting. Saphaneous vein grafts may be attached to the aorta without sutures....
... Nidek GYC-1000 delivers a solid-state ... of energy and plugs into ... compact design and extreme portability, ... with the Nidek Phaco Emulsification ...
There are many reasons to choose the CardioGenesis 2000 Holmium:YAG Laser System for TMR in your hospital or medical facility. Among the first is the CardioGenesis commitment to deliver the highest q...
Total T3 EIA Thyroid Function 025-BC-1005...
Medicine Products: